The women's health initiative estrogen replacement therapy is neurotrophic and neuroprotective

Neurobiology of Aging

Volumn 21, Issue 3, 2000, Pages 475-496

  Diaz Brinton, Roberta ^a   Chen, Shuhua ^a   Montoya, Marissa ^a   Hsieh, Debra ^a   Minaya, Jasmin ^a   Kim, Jeffrey ^a   Chu, Hsiao Pai ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Basal forebrain; Cerebral cortex; Conjugated equine estrogens; Estrogen; Estrogen replacement therapy; Hippocampus; Neuroprotection; Neurotrophism; Premarin

Indexed keywords

AMYLOID BETA PROTEIN; CONJUGATED ESTROGEN; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; COGNITION; CONTROLLED STUDY; ESTROGEN THERAPY; FETUS; FOREBRAIN; HIPPOCAMPUS; NERVE FIBER GROWTH; NEUROPROTECTION; NEUROTOXICITY; NEUROTROPISM; NONHUMAN; PRIORITY JOURNAL; RAT; TEMPORAL CORTEX;

ADENOSINE TRIPHOSPHATE; AGING; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; BRAIN CHEMISTRY; CELL SURVIVAL; CELLS, CULTURED; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); GLUTAMIC ACID; HORSES; HYDROGEN PEROXIDE; L-LACTATE DEHYDROGENASE; MEMORY; NERVOUS SYSTEM; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS;

EID: 0034612076     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(00)00109-3     Document Type: Article

References (59)

1. Behl C. Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease. [review 153] . Cell Tissue Res. 290:1997;471-480.
2. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 77:1994;817-827.
3. Behl C., Skutella T. , Lezoualc, Post, Widmann M, Newton CJ, Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol. 51:1997;535-541.
4. Behl C., Widmann M., Trapp T., Holsboer F. 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun. 216:1995;473-482.
5. Birge S.J. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? [see comments]. [review 79 refs] J Am Geriatr Soc. 44:1996;865-870.
6. Birge S.J. The role of estrogen in the treatment of Alzheimer's disease. [review 55 refs] Neurology. 48:1997a;S36-S41.
7. Birge S.J., Mortel K.F. Estrogen and the treatment of Alzheimer's disease. [review 97 refs] Am J Med. 103:1997b;36S-45S.
8. Boveris A., Cadenas E. Cellular sources and steady-state levels of reactive oxygen species. Clerch L.B., Massaro D.J. Oxygen, Gene Expression, and Cellular Function. 1997;1-25 Marcel Dekker, New York.
9. Brewer G.J., Torricelli J.R., Evege E.K., Price P.J. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res. 35:1993;567-576.
10. Brinton R.D. 17 β-estradiol induction of filopodial growth in cultured hippocampal neurons within minutes of exposure. Mol Cell Neurosci. 4:1993;36-46.
11. Brinton RD, Proffitt P, Tran J, Luu R. Equilin, a principal component of the estrogen replacement therapy premarin, increases the growth of cortical neurons via an NMDA receptor-dependent mechanism. Exp Neurol 1997a;147:211-20.
12. Brinton RD, Tran J, Profitt P, Kahil M. 17 β-estradiol increases the growth and survival of cultured cortical neurons. Neurochem Res 1997b;22:1339-51.
13. Brinton R.D., Yamazaki R.S. Therapeutic advances and challenges in the treatment of Alzheimer's disease. Pharm Res. 15:1998;384-397.
14. Choi D.W. Ionic dependence of glutamate neurotoxicity. J Neurosci. 7:1987;369-379.
15. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. [review 96 refs] . Science. 262:1993;689-695.
16. Fillit H., Weinreb H., Cholst I., Luine V., McEwen B., Amador R., Zabriskie J. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology. 11:1986;337-345.
17. Foy M.R., Xu J., Xie X., Brinton R.D., Thompson R.F., Berger T.W. 17β-estradiol Enhances NMDA Receptor-mediated EPSPs and Long-term Potentiation. J Neurophysiol. 81:1999;925-928.
18. Gazzaley A.H., Weiland N.G., McEwen B.S., Morrison J.H. Differential regulation of NMDAR1 mRNA and protein by estradiol in the rat hippocampus. J Neurosci. 16:1996;6930-6938.
19. Green P.S., Gordon K., Simpkins J.W. Phenolic A ring requirement for the neuroprotective effects of steroids. J Steroid Biochem Mol Biol. 63:1997;229-235.
20. Green P.S., Gridley K.E., Simpkins J.W. Nuclear estrogen receptor-independent neuroprotection by estratrienes a novel interaction with glutathione . Neuroscience. 84:1998;7-10.
21. Greenough W.T., Bailey C. The anatomy of a memory convergence of results across a diversity of tests . TINS. 11:1988;142-147.
22. Honjo H., Ogino Y., Naitoh K., et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem. 34:1989;521-525.
23. Horwitz B. Neuronal plasticity how changes in dendritic architecture can affect the spread of postsynaptic potentials . Brain Res. 224:1981;412-418.
24. Kampen D.L., Sherwin B.B. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 83:1994;979-983.
25. Kawas C., Resnick S., Morrison A., et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease the Baltimore Longitudinal Study of Aging . Neurology. 48:1997;1517-1521.
26. Klein R, Berlin L. Benefits and risks of hormone replacement therapy. In: Pavlik EJ, editor. Estrogens, Progestins, and Their Antagonists. Boston: Birkhäuser, 1996; p. 3-50.
27. Liu J, Shigenaga MK, Mori A, Ames BN. Free Radicals and neurodegenerative disease: stree and oxidative damage. In: Packer L, Hiramatsu M, Yoshikawa T, editors. Free radicals in brain physiology and disorders. San Diego, CA: Academic Press, 1996. p. 403-37.
28. Mainen Z.F., Sejnowski T.J. Influence of dendritic structure on firing pattern in model neocortical neurons. Nature. 382:1996;363-366.
29. Mattson M.P. Calcium as sculptor and destroyer of neural circuitry. [review 90 refs] Exp Gerontol. 27:1992;29-49.
30. 2+ homeostasis in Alzheimer's disease. [review 70 refs] Trends Neurosci. 16:1993;409-414.
31. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., Rydel R.E. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 12:1992;376-389.
32. Mattson M.P., Kater S.B. Excitatory and inhibitory neurotransmitters in the generation and degeneration of hippocampal neuroarchitecture. Brain Res. 478:1989;337-348.
33. Murphy DD, Cole NB, Greenberger V, Segal M. Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci 1998a;18:2550-9.
34. Murphy DD, Cole NB, Segal M. Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Proc Natl Acad Sci USA 1998b;95:11412-7.
35. Murphy D.D., Segal M. Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones. J Neurosci. 16:1996;4059-4068.
36. Paganini-Hill A., Henderson V.W. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 156:1996;2213-2217.
37. Perez V.J., Frantseva M.V., Carlen P.L. In vitro ischemia promotes glutamate-mediated free radical generation and intracellular calcium accumulation in hippocampal pyramidal neurons. J Neurosci. 17:1997;9085-9094.
38. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992a;17:485-95.
39. Phillips SM, Sherwin BB. Variations in memory function and sex steroid hormones across the menstrual cycle. Psychoneuroendocrinology 1992b;17:497-506.
40. Posner M.I., Petersen S.E., Fox P.T., Raichle M.E. Localization of cognitive operations in the human brain. [review 45 refs] Science. 240:1988;1627-1631.
41. Shaywitz S.E., Shaywitz B.A., Pugh K.R., et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA. 281:1999;1197-1202.
42. Sherwin B.B., Tulandi T. "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. [see comments] J Clin Endocrinol Metab. 81:1996;2545-2549.
43. Shumaker S, Rapp S. Hormone replacement therapy in dementia prevention: the Women's Health Initiative Memory Study. Neurobiol Aging 1996;17:534.
44. Singer C.A., Figueroa-Masot X.A., Batchelor R.H., Dorsa D.M. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci. 19:1999;2455-2463.
45. Singh M., Meyer E.M., Millard W.J., Simpkins J.W. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res. 644:1994;305-312.
46. Singh M., Sétáló G. Jr, Guan X., Warren M., Toran-Allerand C.D. Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants convergence of estrogen and neurotrophin signaling pathways . J Neurosci. 19:1999;1179-1188.
47. Solodkin A, Van Hoesen GW. Neuropathology and functional anatomy of Alzheimer's disease. In: Pharmacological treatment of Alzheimer's disease: molecular and neurobiological foundations. New York: John Wiley & Sons, 1997. p. 151-177.
48. Spruston N., Jaffe D.B., Johnston D. Dendritic attenuation of synaptic potentials and currents the role of passive membrane properties . [review 24 refs] Trends Neurosci. 17:1994;161-166.
49. Tang M.X., Jacobs D., Stern Y., et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. [see comments] Lancet. 348:1996;429-432.
50. Toran-Allerand C.D. Organotypic culture of the developing cerebral cortex and hypothalamus relevance to sexual differentiation . [review 96 refs] Psychoneuroendocrinology. 16:1991;7-24.
51. United States Pharmacy Convention I. United States Pharmacopeia 1995, Reference Text, Conjugated Estrogens. In: United States Pharmacopeia 1995 (Anonymous pp. 627-9. Rand McNally, MA.: United States Pharmacy Convention, Inc, 1995.
52. Warren S.G., Humphreys A.G., Juraska J.M., Greenough W.T. LTP varies across the estrous cycle enhanced synaptic plasticity in proestrus rats . Brain Res. 703:1995;26-30.
53. Wong M., Moss R.L. Long-term and short-term electrophysiological effects of estrogen on the synaptic properties of hippocampal CA1 neurons. J Neurosci. 12:1992;3217-3225.
54. Woolley CS, McEwen BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat [published erratum appears in J Neurosci 1992 Oct;12(10): following table of contents]. J Neurosci 1992;12:2549-54.
55. Woolley CS, McEwen BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat [published erratum appears in J Neurosci 1992 Oct;12(10): following table of contents]. J Neurosci 1992;12:2549-54.
56. Woolley C.S., McEwen B.S. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol. 336:1993;293-306.
57. Woolley C.S., McEwen B.S. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci. 14:1994;7680-7687.
58. Woolley C.S., Weiland N.G., McEwen B.S., Schwartzkroin P.A. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input correlation with dendritic spine density . J Neurosci. 17:1997;1848-1859.
59. Wysowski D.K., Golden L., Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol. 85:1995;6-10.